billHR8103Event Thursday, March 26, 2026Analyzed

To prohibit the use of funds to use military force in or against Cuba, and for other purposes.

Neutral

Summary

HR8103 is a procedural early-stage bill that prohibits funding for unauthorized military force in or against Cuba until December 31, 2026. It has zero direct spending, zero mandated cuts, and zero impact on any existing defense program because there are no active U.S. military operations in or against Cuba. This bill removes a hypothetical tail risk that markets have never priced. No market impact is justified. The bill remains in committee with a long legislative path and no companion Senate bill.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR8103 has zero funding, zero mandated cuts, and zero impact on any existing defense program or contract.
  • 2.No active U.S. combat operations exist in or against Cuba — this bill preempts a scenario that does not exist and was never in any analyst forecast.
  • 3.The bill has no Senate companion, zero Republican cosponsors, and is stuck in committee — probability of passage in the 119th Congress is negligible.

Market Implications

No market implications. HR8103 is a procedural early-stage bill with no funding, no mandate, and no structural effect on any publicly traded company. Defense stocks LMT ($475), RTX ($125), NOC ($485), and GD ($300) trade on FY2026 NDAA baselines, budget agreements, and international demand — not on the remote possibility of a Cuba conflict authorization. Markets have correctly priced this bill at zero impact. There is no actionable signal for retail investors.

Full Analysis

What happened: On March 26, 2026, Rep. Jayapal (D-WA) introduced HR8103, a bill prohibiting the use of federal funds for military force in or against Cuba unless Congress declares war or enacts specific statutory authorization. The bill was referred to the House Foreign Affairs and Armed Services Committees. It has 31 Democratic co-sponsors, no Republican co-sponsors, and no Senate companion bill.

The money trail: This is an authorization-level prohibition with zero dollar amounts. It does not authorize, appropriate, or cut any funding. It places a condition on how existing and future appropriations may be spent. The prohibition expires on December 31, 2026. Because there are no existing combat operations in or against Cuba, no funding is currently obligated or expended for such purposes. The exception for uses consistent with Section 2(c) of the War Powers Resolution covers defensive and rescue operations, which already covers current Guantanamo Bay operations.

Structural winners and losers: No company is a winner or loser from this bill. Defense primes LMT, RTX, NOC, and GD have no active contracts or programs tied to Cuban combat operations. The bill does not affect any existing authorization (e.g., NDAA programs) or appropriation. It is purely preemptive legislation that removes a hypothetical scenario. The bill has zero structural impact on defense procurement, sustainment, or services revenue.

Timeline: HR8103 is in early-stage committee referral. To become law, it must pass the full House, the Senate (no companion bill exists), survive a potential presidential veto (unlikely given White House support is speculative), and become enacted before the December 31, 2026 sunset. Probability of enactment in the 119th Congress with a Republican-controlled House and Senate is very low. Even if enacted, the sunset date ensures the prohibition would be short-lived.

Conclusion: This is a messaging bill with zero market consequences. Retail investors should ignore HR8103 entirely. There is no actionable trading thesis, no sector rotation signal, and no company-level revenue impact.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$LMT● Neutral
0

What the bill does

Prohibition on obligated or expended funds for any use of military force in or against Cuba unless Congress declares war or enacts specific statutory authorization, except for uses consistent with Section 2(c) of the War Powers Resolution (defensive action to protect U.S. personnel/prevent imminent attack).

Who must act

Department of Defense, any Federal agency with appropriated funds for military operations

What happens

Eliminates the possibility of a new, conflict-driven supplemental appropriations bill for operations in or against Cuba during the prohibition period (through Dec 31, 2026). No existing U.S. military operations in Cuba are affected because none exist; the bill is purely preemptive. Current Cuba-related spending is limited to Guantanamo Bay base operations and migration/asylum detention, which fall under the War Powers exception. Zero expected change in baseline defense demand.

Stock impact

LMT derives ~35% of revenue from F-35 and integrated air/missile defense systems. This bill precludes a new theater of operations that would have driven sustainment and munitions demand. However, the baseline scenario already assumed no conflict with Cuba. Zero incremental revenue effect — the bill removes a hypothetical tail risk that markets never priced in.

$$RTX● Neutral
0

What the bill does

Same prohibition on obligated/expended funds for military force in or against Cuba.

Who must act

Department of Defense, federal agencies

What happens

Same structural analysis as above — no existing combat operations in Cuba. No supplemental spending aversion or activation. Raytheon's missile/DAS business (Patriot, AMRAAM, Standard Missile) sees no change in order book. The prohibition removes only a hypothetical future combat demand scenario that was not part of forward guidance or consensus estimates.

Stock impact

RTX's Raytheon segment (air & missile defense, sensors) represents ~40% of sales. No Cuban contingency orders were in any analyst model. Net effect: zero. Markets have correctly ignored this bill.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

presidential_memorandumJun 12, 2026

National Security Presidential Memorandum/NSPM-12

This memorandum rescinds previous national security directives and re-establishes the Committee on National Security Systems (CNSS) to enforce baseline cybersecurity standards across all National Security Systems (NSS) operated by the Department of War, Intelligence Community, and Federal Civilian Executive Branch agencies. It creates binding directives and complementary standards that must meet or exceed NIST guidelines, empowers the NSA Director as the National Manager to issue emergency directives and cryptography requirements, and holds agency heads accountable through government-wide oversight.

presidential_memorandumJun 5, 2026

National Security Presidential Memorandum/NSPM-11

This memorandum directs the national security enterprise (including the Department of War, intelligence agencies, and others) to accelerate the adoption, adaptation, and assurance of AI technologies for military and intelligence missions. It mandates updates to DOD Directive 3000.09 on autonomous weapons within 90 days, requires termination of contracts with companies that repeatedly violate policy (e.g., by enabling adversary control or embedding bias), and emphasizes supply chain resilience and multi-vendor sourcing to avoid single-vendor dependencies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.